Swiss pharmaceutical company Ciba has inaugurated a new production center in Barbera del Valles near Barcelona in Spain. The production center forms part of a new integrated Europe-wide manufacturing organization for the pharmaceuticals division.
The plant is one of three that Ciba has within its EFI Project, which focuses on Spain, France and Italy. Ciba says that the project is in keeping with its strategy to adapt its activities in Europe. Pharmaceutical production must be concentrated on a small number of production centers which will cover the entire European market. Each of these centers will produce defined specialties destined for European Union countries.
The new facility at Barbera del Valles, which is also where Ciba's Spanish company is located, will manufacture small quantities of solid drug forms. The Italian plant in Torre Annunziata at the foot of Mount Vesuvius is responsible for large-scale production of solid drugs for oral administration, while in France, Laboratoires Ciba-Geigy manufactures non-solid drug forms, such as suppositories, creams, syrups, drops and ampoules.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze